Aetna modified CPB 0991 for fosdenopterin (Nulibry), effective December 20, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its Aetna fosdenopterin coverage policy under CPB 0991 in the Aetna clinical policy bulletin system. The modification affects claims billed under HCPCS J1809 (injection, fosdenopterin, 0.1 mg) and infusion administration codes CPT 96413–96417. If your practice or specialty pharmacy treats patients with molybdenum cofactor deficiency (MoCD) type A, this coverage policy update changes what documentation you need at authorization and continuation.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Fosdenopterin (Nulibry) — CPB 0991 |
| Policy Code | CPB 0991 |
| Change Type | Modified |
| Effective Date | December 20, 2025 |
| Impact Level | High |
| Specialties Affected | Metabolic/enzyme disorder specialists, infusion billing teams, specialty pharmacy |
| Key Action | Update your prior authorization packets to include MOCS1 genetic testing results or document pending status with clinical signs before submitting claims for J1809 |
Aetna Fosdenopterin Coverage Criteria and Medical Necessity Requirements 2025
Fosdenopterin (Nulibry) billing starts with prior authorization. Aetna requires precertification for every claim. Call (866) 752-7021 or fax your Statement of Medical Necessity to (888) 267-3277 before treatment begins.
The prescriber requirement is strict. This drug must be prescribed by — or in documented consultation with — a physician who specializes in enzyme or metabolic disorders. A general neurologist or pediatrician ordering Nulibry without that specialist involvement will get denied. Document the specialist's role explicitly in the chart before you submit.
For initial approval, Aetna considers fosdenopterin medically necessary for MoCD type A under two scenarios. The first and cleanest path is confirmed genetic testing showing a pathogenic variant in the MOCS1 gene. If that result is in hand, your prior authorization documentation is straightforward — attach the genetic test report.
The second path is for urgent situations where genetic testing is still pending. Aetna will consider a presumed MoCD type A diagnosis medically necessary when the member shows clinical signs: encephalopathy, intractable seizures, developmental delay, decreased uric acid levels, or elevated urinary S-sulfocysteine and/or xanthine levels. Both the pending test documentation and the clinical presentation must be in your authorization packet. One without the other won't satisfy this coverage policy.
The real issue here is documentation sequencing. Billing teams often submit auth requests before the chart is complete. With fosdenopterin billing, that's a guaranteed denial. Lock in the clinical documentation — genetic results or pending-plus-symptoms — before you pick up the phone to call precertification.
Aetna Fosdenopterin Exclusions and Non-Covered Indications
Aetna is explicit: all indications outside of MoCD type A are experimental, investigational, or unproven. There are no other covered uses under CPB 0991.
MoCD has three types — A, B, and C. Only type A qualifies. If you're treating a patient with type B or type C MoCD, fosdenopterin billing under HCPCS J1809 will be denied. The same applies to any off-label use for other sulfur-bearing amino acid metabolism disorders. ICD-10 code E72.19 covers a range of conditions — submitting claims with E72.19 without confirmed MoCD type A documentation is a claim denial waiting to happen.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| MoCD type A — confirmed MOCS1 pathogenic variant via genetic testing | Covered | J1809, E72.19, CPT 96413–96417 | Prior authorization required; genetic test report must be on file |
| MoCD type A — presumed diagnosis, genetic testing pending, clinical signs present | Covered (conditional) | J1809, E72.19, CPT 96413–96417 | Both pending test documentation AND clinical signs required; prior auth required |
| Continuation <12 months — MOCS1 genetic testing confirms pathogenic variant | Covered | J1809, E72.19, CPT 96413–96417 | Genetic confirmation required for continuation under 12 months |
| Continuation ≥12 months — demonstrated clinical benefit | Covered | J1809, E72.19, CPT 96413–96417 | Must document improvement, stabilization, or slowed progression of encephalopathy, seizures, or lab markers |
| MoCD type B or type C | Not Covered | — | Not a covered indication under CPB 0991 |
| All other indications | Experimental / Not Covered | — | Aetna considers all other uses experimental, investigational, or unproven |
Aetna Fosdenopterin Billing Guidelines and Action Items 2025
The effective date for this modification is December 20, 2025. If you have patients currently on fosdenopterin or anticipate starting new patients, act before that date.
| # | Action Item |
|---|---|
| 1 | Update your prior authorization template for J1809 immediately. Your auth packet needs one of two things: a genetic test report confirming a pathogenic MOCS1 variant, or documentation that testing is pending plus clinical sign documentation (encephalopathy, seizures, developmental delay, uric acid, S-sulfocysteine, xanthine levels). Generic "MoCD type A diagnosis" without supporting documentation is not enough. |
| 2 | Verify the prescribing physician's specialty before submission. Aetna requires the prescriber to be — or to have consulted with — an enzyme or metabolic disorder specialist. Pull that documentation into the auth file. If you're billing on behalf of a practice where a generalist placed the order, get the specialist consultation note before December 20, 2025. |
| 3 | Audit your active fosdenopterin patients for continuation criteria. Patients under 12 months of therapy need confirmed MOCS1 genetic results on file — not pending. Patients at or past 12 months need documented clinical benefit: improvement or stabilization of encephalopathy or seizures, or normalized uric acid, urinary S-sulfocysteine, and xanthine levels. If that documentation isn't in the chart, you're at risk for a claim denial at the next renewal. |
| 4 | Bill infusion administration correctly alongside J1809. Fosdenopterin is administered intravenously. Use CPT 96413 for the initial infusion hour. Use CPT 96415 for each additional hour. CPT 96414 applies to concurrent infusions. CPT 96416 covers initiation of prolonged chemotherapy infusion (more than eight hours). CPT 96417 applies to each additional sequential infusion of a different drug. Q0084 and Q0085 are the corresponding HCPCS infusion codes — use whichever your facility requires. Don't default to one code without checking payer-specific billing guidelines for infusion sequencing. |
| 5 | Use ICD-10 code E72.19 precisely — and document why it applies. E72.19 covers "other disorders of sulfur-bearing amino-acid metabolism," which includes MoCD type A. But it's a catch-all code. Your claim needs supporting documentation that specifically identifies MoCD type A — not just the ICD-10 code. Pair E72.19 with the genetic testing results or the clinical workup in every chart. |
| 6 | If you're billing specialty pharmacy and medical benefit separately, confirm benefit coordination. J1809 is a medical benefit drug when administered in an infusion setting. Make sure your team is not inadvertently submitting to pharmacy benefit as well. Duplicate billing will trigger a claim denial and, depending on your payer contract, a recoupment request. |
| 7 | Loop in your compliance officer if your patient population includes any off-label MoCD cases. If you have patients with type B or type C MoCD who are receiving fosdenopterin, get compliance involved before December 20, 2025. This is not a gray area — Aetna has no covered indication outside type A. Any claims submitted for those patients will deny, and repeated denials without corrective action create audit exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Fosdenopterin (Nulibry) Under CPB 0991
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1809 | HCPCS | Injection, fosdenopterin, 0.1 mg |
Other CPT Codes Related to CPB 0991 (Infusion Administration)
These codes cover the IV infusion administration of fosdenopterin. They are not stand-alone covered codes — they apply when J1809 is covered and the infusion is billed separately.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique — up to one hour |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique — concurrent infusion |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique — each additional hour |
| 96416 | CPT | Chemotherapy administration, intravenous infusion technique — initiation of prolonged infusion (>8 hours) |
| 96417 | CPT | Chemotherapy administration, intravenous infusion technique — each additional sequential infusion, different drug |
Other HCPCS Codes Related to CPB 0991
| Code | Type | Description |
|---|---|---|
| Q0084 | HCPCS | Chemotherapy administration, infusion technique |
| Q0085 | HCPCS | Chemotherapy administration, infusion technique |
Key ICD-10-CM Diagnosis Code
| Code | Description |
|---|---|
| E72.19 | Other disorders of sulfur-bearing amino-acid metabolism [molybdenum cofactor deficiency (MoCD) type A] |
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.